BM samples | Parameter | Hazard ratio | 95% CI | P-values |
---|---|---|---|---|
Systemic recurrence-free survival | ||||
BM1 | DTC status (pos. vs. neg.) | 5.944 | 2.713–13.022 | <0.001 |
BM2* | DTC status (pos. vs. neg.) | 5.013 | 2.133–11.782 | <0.001 |
BM3* | DTC status (pos. vs. neg.) | 3.680 | 1.062–12.744 | 0.040 |
BM2 and/or BM3 | DTC status (pos. vs. neg.) | 4.523 | 2.044–10.008 | <0.001 |
BM1 and BM2/3 | DTC status (pos. vs. neg.) | 9.948 | 4.103–24.122 | <0.001 |
Lymph node status (pN > 0 vs. pN0) | 3.995 | 1.833–8.708 | <0.001 | |
Tumor size (pT3 and pT4 vs. pT2 vs. pT1) | 1.523 | 0.691–3.358 | 0.297 | |
Tumor grade (3 vs. 2 vs. 1) | 2.015 | 1.212–3.352 | 0.007 | |
Age (>55 or not) | 1.044 | 0.484–2.252 | 0.913 | |
ER (positive vs. negative) | 0.322 | 0.143–0.723 | 0.006 | |
PgR (positive vs. negative) | 0.735 | 0.337–1.605 | 0.440 | |
Adjuvant chemotherapy (received or not) | 1.603 | 0.713–3.601 | 0.253 | |
Adjuvant endocrine therapy (received or not) | 1.814 | 0.832–3.951 | 0.134 | |
Breast-cancer specific survival | ||||
BM1 | DTC status (pos. vs. neg.) | 5.408 | 2.271–12.880 | <0.001 |
BM2* | DTC status (pos. vs. neg.) | 3.880 | 1.470–10.238 | 0.006 |
BM3* | DTC status (pos. vs. neg.) | 4.626 | 1.286–16.635 | 0.019 |
BM2 and/or BM3 | DTC status (pos. vs. neg.) | 3.851 | 1.592–9.316 | 0.003 |
BM1 and BM2/3 | DTC status (pos. vs. neg.) | 9.205 | 3.526–24.031 | <0.001 |
Lymph node status (pN > 0 vs. pN0) | 4.694 | 1.944–11.344 | 0.001 | |
Tumor size (pT3 and pT4 vs. pT2 vs. pT1) | 1.788 | 0.753–4.247 | 0.188 | |
Tumor grade (3 vs. 2 vs. 1) | 3.288 | 1.743–6.201 | <0.001 | |
Age (>55 or not) | 1.384 | 0.583–3.284 | 0.461 | |
ER (positive vs. negative) | 0.217 | 0.091–0.516 | 0.001 | |
PgR (positive vs. negative) | 0.729 | 0.306–1.733 | 0.474 | |
Adjuvant chemotherapy (received or not) | 1.545 | 0.623–3.833 | 0.348 | |
Adjuvant endocrine therapy (received or not) | 1.820 | 0.766–4.324 | 0.175 |